These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 8561475)
41. Genetic dissection of immunity to mycobacteria: the human model. Casanova JL; Abel L Annu Rev Immunol; 2002; 20():581-620. PubMed ID: 11861613 [TBL] [Abstract][Full Text] [Related]
42. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy. Lu M; Xia ZY; Bao L Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251 [TBL] [Abstract][Full Text] [Related]
43. New pathways of protective and pathological host defense to mycobacteria. Ottenhoff TH Trends Microbiol; 2012 Sep; 20(9):419-28. PubMed ID: 22784857 [TBL] [Abstract][Full Text] [Related]
44. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Tomioka H Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623 [TBL] [Abstract][Full Text] [Related]
45. Progress in the immunology of the mycobacterioses. Rook GA Clin Exp Immunol; 1987 Jul; 69(1):1-9. PubMed ID: 3308222 [No Abstract] [Full Text] [Related]
46. The immunology of mycobacterial infections. Chaparas SD Crit Rev Microbiol; 1982; 9(2):139-97. PubMed ID: 7042210 [TBL] [Abstract][Full Text] [Related]
47. Correcting the record on BCG before we license new vaccines against tuberculosis. von Reyn CF J R Soc Med; 2017 Nov; 110(11):428-433. PubMed ID: 28949270 [No Abstract] [Full Text] [Related]
48. Advances in mycobacterial genetics: new promises for old diseases. Jacobs WR Immunobiology; 1992 Feb; 184(2-3):147-56. PubMed ID: 1587540 [No Abstract] [Full Text] [Related]
49. [Tuberculosis and its control--lessons from the past and future prospect]. Shimao T Kekkaku; 2005 Jun; 80(6):481-9. PubMed ID: 16130906 [TBL] [Abstract][Full Text] [Related]
50. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Schuring RP; Richardus JH; Pahan D; Oskam L Vaccine; 2009 Nov; 27(50):7125-8. PubMed ID: 19786134 [TBL] [Abstract][Full Text] [Related]
51. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. Payen MC; De Wit S; Clumeck N Rev Mal Respir; 1997 Dec; 14 Suppl 5():S142-51. PubMed ID: 9496599 [TBL] [Abstract][Full Text] [Related]
53. Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine. Kaufmann SH; Andersen P Chem Immunol; 1998; 70():21-59. PubMed ID: 9509669 [No Abstract] [Full Text] [Related]
54. Editorial: Mycobacterial Glycolipids-Role in Immunomodulation and Targets for Vaccine Development. Källenius G; Nigou J; Cooper A; Correia-Neves M Front Immunol; 2020; 11():603900. PubMed ID: 33133110 [No Abstract] [Full Text] [Related]
55. The promise of immunotherapy for tuberculosis. Stanford JL; Grange JM Respir Med; 1994 Jan; 88(1):3-7. PubMed ID: 8029511 [No Abstract] [Full Text] [Related]
57. The immunology of mycobacterial diseases. Edwards D; Kirkpatrick CH Am Rev Respir Dis; 1986 Nov; 134(5):1062-71. PubMed ID: 3535595 [No Abstract] [Full Text] [Related]
58. New concepts for the control of tuberculosis in the twenty first century. Stanford JL; Grange JM J R Coll Physicians Lond; 1993 Jul; 27(3):218-23. PubMed ID: 8377152 [TBL] [Abstract][Full Text] [Related]
59. Genetic susceptibility to mycobacterial disease in humans. Fernando SL; Britton WJ Immunol Cell Biol; 2006 Apr; 84(2):125-37. PubMed ID: 16519730 [TBL] [Abstract][Full Text] [Related]
60. [Towards new strategies to combat mycobacterial diseases]. Kobayashi K Nihon Hansenbyo Gakkai Zasshi; 1997 Nov; 66(3):191-8. PubMed ID: 9513344 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]